Clinical trial
A Phase II Trial Investigating the Benefit of Immunotherapy With Durvalumab After Autologous Transplant in High-risk Diffuse-large B-cell Lymphomas (the IDA-D Trial)
NCT03241017 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial Investigating the Benefit of Immunotherapy With Durvalumab After Autologous Transplant in High-risk Diffuse-large B-cell Lymphomas (the IDA-D Trial)
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- October 31, 2017
- Completion date
- December 31, 2021
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.